Safety study of MMV371 injection for malaria prevention
Part of Infections clinical trials.
This study tests a new long-acting malaria prevention injection (MMV371) in healthy adults and adolescents in Rwanda. Researchers will monitor how safe it is and how your body processes it over 24 weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12–50 years old and in good overall health
- You can commit to all study visits, blood tests, and injections for 24 weeks
- You live near the trial site in Rwanda and can stay for the full study
- If female: you are not pregnant, not breastfeeding, and willing to use contraception
- You have not taken part in another drug study in the last 90 days
- You do not have malaria, HIV, hepatitis B or C, or serious heart, liver, kidney, or bleeding conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new malaria drug (MMV055), alone or with another drug (MMV371), to see if it is safe and how the body processes it. It is for healthy people who want to help find new malaria treatments.
This study screens healthy adults to see who can join future malaria vaccine or investigational malaria drug studies, including a controlled malaria exposure. It may help researchers test safer vaccines/drugs, but participation requires good health and strict medical eligibility.
This study tests an experimental malaria vaccine (CVD 36000) in healthy volunteers aged 18–50. Researchers will give you the vaccine and later expose you to malaria parasites in a controlled setting to see if the vaccine protects you. This helps develop a safer vaccine for people in malaria-prone countries.
This study compares two experimental malaria vaccines to see how safe they are and how well they protect adults. It may help future malaria prevention, and you would be closely monitored, including a malaria “challenge” test if you qualify.
This trial uses a genetically modified malaria parasite given by mosquito bite to safely test a new vaccine approach in healthy volunteers. If you qualify, you'll help researchers understand how the body defends against malaria.
This trial tests a new combination of experimental malaria vaccines to see if they are safe and help protect against malaria. It includes both adults and young children in malaria-affected areas.
Hear when a new Malaria (Plasmodium Falciparum) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.